Features of the functioning of dopaminergic and serotonergic neurotransmitter systems of some parts of the rat brain after AZT (zidovudine) and S-adenosyl-L-methionine drugs administration

Zidovudine (AZT) is an antiretroviral drug that has proven itself not only in treating HIV infection, but is associated with side effects on the central nervous system. All psychopathological symptoms are based on the processes of activation and inhibition of neurotransmitter systems, therefore, the purpose of this work was a comparative study of indi­cators characterizing the main monoaminergic systems of the brain of rats, including levels of amino acids precursors and metabolites, in different parts of the brain of rats when exposed to drugs zidovudine (AZT) and heptral (SAM) individually and in combination; to evaluate a possible corrective effect of S-adenosyl-L-methionine under experimental conditions. The latter has a potential neuroprotective effect on improving cognitive impairment during brain aging, which is associated with inhibiting oxidative stress and neuroinflammation. The results of the experiment showed that the effect of AZT is reflected to a greater extent on the functioning of the dopaminergic neurotransmitter system of the hypothalamus (increased dopamine levels), the striatum and midbrain of rats (decreased neurotransmitter content), an increase in serotonin concentration was noted only in the midbrain. The use of SAM against the background of AZT led to normalizing the dopamine content in the hypothalamus, striatum and brain stem of rats, serotonin - in the stem, which indicates the corrective effect of the drug on the studied neurotransmitter systems. The combined use of SAM and AZT leads to increasing serotonin concentrations in all studied parts of the brain of rats and are close to the values in the group of animals treated only with SAM.

1. Rubin L. H., Maki P. M. HIV, depression and cognitive impairment in the era of effective antiretroviral therapy. Current HIV/AIDS Report, 2019, vol. 16, no. 1, pp. 82-95. https://doi.org/10.1007/s11904-019-00421-0

2. Schneider M. A., Buzdin A. A. Combination of antiretroviral drugs Zidovudine and Efavirenz impairs tumor growths in a mouse model of cancer. Viruses, 2021, vol. 13, no. 12, p. 2396. https://doi.org/10.3390/v13122396

3. Shafiee A., Seighali N. Alfa based regimens for the treatment of adult T-cell leukemia/lymphoma (ATLL): a systematic review and meta-analysis. Virological Journal, 2023, vol. 20, p. 118. https://doi.org/10.1186/s12985-023-02077-0

4. Sukiasyan S. G. Brain and mentality: biological foundations of psychiatry. Sciences of Europe, 2022, vol. 90, pp. 42-53 (in Russian).

5. Fu R., Jinnah H., Mckay J. L., Miller A. H., Felger J. C., Farber E. W., Sharma S., Whicker N. Cerebrospinal fluid levels of 5-HIAA and dopamine in people with HIV and depression. Journal of Neurovirology, 2023, vol. 29, pp. 440-448. https://doi.org/10.1007/s13365-023-01142-2

6. De Berardis D., Orsolini L., Serroni N., Girinelli G., Iasevoli F., Tomasetti C. A comprehensive review on the efficacy of S-adenosyl-L-methionine in major depressive disorder. CNS Neurological Disorder Drug Targets, 2016, vol. 15, no. 1, pp. 35-44. https://doi.org/10.2174/1871527314666150821103825

7. Zhang Y., Ma R., Deng Q., Wang W., Cao Ch., Yu Ch. S-adenosylmethionine improves cognitive impairment in D-galactose-induced brain aging by inhibiting oxidative stress and neuroinflammation. Journal of Chemical Neuroanatomy, 2023, vol. 128, p. 102232. https://doi.org/10.1016/j.jchemneu.2023.102232

8. Otero-Losada M. E., Rubio M. C. Acute changes in 5-HT metabolism after S-adenosyl-L-methionine administration. General Pharmacology, 1989, vol. 20, no. 4, pp. 403-406. https://doi.org/10.1016/0306-3623(89)90186-9

9. Sharma A., Gerbarg P., Bottiglieri T., Massoumi L., Carpenter L., Lavretsky H., Muskin Ph., Brown R., Mischoulon D. S-Adenosylmethionine (SAMe) for neuropsychiatric disorders: A clinical-oriented review of research. Journal of Clinical Psychiatry, 2017, vol. 78, no. 6, pp. 656-667. https://doi.org/10.4088/jcp.16r11113

10. Doroshenko E. M., Lelevich V. V. Biogenic monoamines, their precursors and metabolites in the brain of rats with experimental circulatory insufficiency. Neirokhimiya [Neurochemistry], 2020, vol. 37, no. 3, pp. 240-248 (in Russian).

11. Mdanda S., Ntshangase S., Singh S. D., Naicker T., Kruger H. G., Baijnath S., Govender Th. Zidovudine and Lamivudine as potential agents to combat HIV-associated neurocognitive disorder. Drug Development Technologies, 2019, vol. 17, no. 7, pp. 322-329. https://doi.org/10.1089/adt.2019.941

12. Gurevich E. V., Gainetdinov R. R., Gurevich V. V. G protein-coupled receptor kinases as regulators of dopamine receptor functions. Pharmacology Resourse, 2016, vol. 111, pp. 1-16. https://doi.org/10.1016/j.phrs.2016.05.010

13. Gatch M. B., Kozlenkov A., Huang R., Yang W., Nguyen J., Gonzalez-Maeso J., Rice K. C., France Ch., Dillon G. The HIV antiretroviral drug efavirenz has LSD-like properties. Neuropsychopharmacology, 2013, vol. 38, no. 12, pp. 2373-2384. https://doi.org/10.1038/npp.2013.135

14. Bertrand L., Velichkovska M., Tobore M. Cerebral vascular toxicity of antiretroviral therapy. Journal of Neuroimmune Pharmacology, 2021, vol. 16, no. 1, pp. 74-89. https://doi.org/10.1007/s11481-019-09858-x